Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Australian Pharmaceutical Industries Limited
ABN	57 000 004 320

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Craig Vincent
Date of last notice	15 October 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		
Date of change	8 February 2022	
No. of securities held prior to change	481,833 ordinary shares 495,711 performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2019 to 31 August 2022 825,400 performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2020 to 31 August 2023 160,900 performance rights granted under API's Short term Incentive Plan	
Class	Performance Rights	

⁺ See chapter 19 for defined terms.

Number disposed Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Rights. If the specific performance contunder the Long Term Incentive Plan are Performance Rights will vest and Mr V will be entitled to convert each Performance Right into one fully pair ordinary share. Vesting of performance is subject to performance period community September 2021 and ending 31 A 2024. No. of securities held after change No. of securities held after change 481,833 ordinary shares (no change) 495,711 performance rights granted API's Long Term Incentive Plan was performance period of 1 September 20 31 August 2022 (no change) 825,400 performance rights granted API's Long Term Incentive Plan was performance period of 1 September 20 31 August 2023 (no change) 160,900 performance rights granted API's Long Term Incentive Plan was performance period of 1 September 20 31 August 2023 (no change) 160,900 performance rights granted API's Long Term Incentive Plan was performance period of 1 September 20 31 August 2024 (no change) 160,900 performance rights granted API's Long Term Incentive Plan was performance period of 1 September 20 31 August 2024 (new) TOTAL: 481,833 ordinary shares 2,213,741 performance rights		721 720 monformance as sights asset 1	Number acquired
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Rights. If the specific performance contunder the Long Term Incentive Plan are Performance Rights will vest and Mr V will be entitled to convert each Performance Right into one fully pain ordinary share. Vesting of performance is subject to performance period commet 1 September 2021 and ending 31 A 2024. No. of securities held after change 481,833 ordinary shares (no change) 495,711 performance rights granted API's Long Term Incentive Plan with performance period of 1 September 2031 August 2022 (no change) 825,400 performance rights granted API's Long Term Incentive Plan with performance period of 1 September 2031 August 2023 (no change) 160,900 performance rights granted API's Short term Incentive Plan (no change) 160,900 performance rights granted API's Long Term Incentive Plan (no change) 160,900 performance rights granted API's Long Term Incentive Plan (no change) 1731,730 performance rights granted API's Long Term Incentive Plan with performance period of 1 September 2031 August 2024 (new) TOTAL: 481,833 ordinary shares 2,213,741 performance rights Nature of change Performance rights were granted under	Plan with a	API's Long Term Incentive Plan wi performance period of 1 September 202	Number acquired
Solution is non-cash, provide details and estimated valuation Rights. If the specific performance condunder the Long Term Incentive Plan ar Performance Right into one fully pain ordinary share. Vesting of performance is subject to performance conditions met over a performance period communal September 2021 and ending 31 August 2024. No. of securities held after change No. of securities held after change 481,833 ordinary shares (no change) 495,711 performance rights granted API's Long Term Incentive Plan veriformance period of 1 September 20 31 August 2022 (no change) 825,400 performance rights granted API's Long Term Incentive Plan veriformance period of 1 September 20 31 August 2023 (no change) 160,900 performance rights granted API's Short term Incentive Plan (no change) 160,900 performance rights granted API's Long Term Incentive Plan veriformance period of 1 September 20 31 August 2024 (new) TOTAL: 481,833 ordinary shares 2,213,741 performance rights Nature of change Performance rights were granted under		Nil	Number disposed
495,711 performance rights granted API's Long Term Incentive Plan was performance period of 1 September 20 31 August 2022 (no change) 825,400 performance rights granted API's Long Term Incentive Plan was performance period of 1 September 20 31 August 2023 (no change) 160,900 performance rights granted API's Short term Incentive Plan (no change) 731,730 performance rights granted API's Long Term Incentive Plan was performance period of 1 September 20 31 August 2024 (new) TOTAL: 481,833 ordinary shares 2,213,741 performance rights	Performance ace conditions Plan are met, d Mr Vincent each vested ally paid API rmance rights ditions being commencing	No amount is payable by Mr Vincent for grant or on the exercise of the Perform Rights. If the specific performance conditions the Long Term Incentive Plan are Performance Rights will vest and Mr Vin will be entitled to convert each vor Performance Right into one fully paid ordinary share. Vesting of performance r is subject to performance conditions the met over a performance period comment over a performance period comment 1 September 2021 and ending 31 Au 2024.	Note: If consideration is non-cash, provide details and estimated valuation
	granted under Plan with a mber 2019 to granted under Plan with a mber 2020 to granted under (no change) granted under Plan with a mber 2021 to	495,711 performance rights granted to API's Long Term Incentive Plan with performance period of 1 September 20131 August 2022 (no change) 825,400 performance rights granted to API's Long Term Incentive Plan with performance period of 1 September 20231 August 2023 (no change) 160,900 performance rights granted to API's Short term Incentive Plan (no change) 731,730 performance rights granted to API's Long Term Incentive Plan with performance period of 1 September 20231 August 2024 (new) TOTAL: 481,833 ordinary shares	No. or securities nero after change
securities under dividend reinvestment plan, participation in buy-back		Performance rights were granted under A Long Term Incentive Plan (2021-2024).	Example: on-market trade, off-market trade, exercise of options, issue of

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

Detail of contract	n/a
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – *Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	n/a
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.